Literature DB >> 7640141

Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.

P J Anderson1, J A Critchley, B Tomlinson, G Resplandy.   

Abstract

1. The pharmacokinetics of perindopril and perindoprilat and the hormonal and haemodynamic responses following a single oral dose were studied in 12 Chinese and 10 Caucasian healthy, normotensive volunteers on two occasions. Perindopril was given on the first occasion as a 4 mg dose and then after at least 10 days as a weight-adjusted dose of 4 mg/70 kg. Plasma was sampled for assay of perindopril, perindoprilat, plasma renin activity (PRA), aldosterone, angiotensin I (AI) and ACE activity. Urine was collected for perindopril and perindoprilat assay. A radioimmunoassay technique was used to measure the prodrug and its active metabolite. 2. The time to maximum concentration (tmax) for perindopril was shorter for the Chinese group after the 4 mg dose (median 0.5, range 0.5-1.5 h vs median 1.0, 0.5-1.5 h P < 0.05) and also tended to be shorter after the weight-adjusted dose (median 0.5, range 0.5-1.0 h vs median 1.0, range 0.5-3.0 h). Cmax and AUC tended to be higher after the 4 mg dose in the Chinese group who had a lower body weight than the Caucasians. 3. The tmax of perindoprilat tended to be shorter for both doses and there was a tendency towards a higher Cmax after the 4 mg dose in the Chinese group but there was no statistically significant difference between the two groups. 4. There were no differences in the levels of PRA, plasma AI, plasma aldosterone or the degree of ACE-inhibition for either dose in the two ethnic groups. 5. Blood pressure was measured at intervals up to 24 h post-dose in both the supine and standing positions. Perindopril reduced blood pressure acutely with respect to the pre-dose level with good tolerability in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640141      PMCID: PMC1365122          DOI: 10.1111/j.1365-2125.1995.tb04463.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

2.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.

Authors:  H H Zhou; R P Koshakji; D J Silberstein; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

3.  Peripheral haemodynamic effects of perindopril compared in patients with congestive heart failure and in normal volunteers.

Authors:  C Thuillez; C Richard; C Richer; H Loueslati; L Perret; P Auzépy; J F Giudicelli
Journal:  J Hypertens Suppl       Date:  1988-12

4.  Effect of charcoal-broiled beef on antipyrine and theophylline metabolism.

Authors:  A Kappas; A P Alvares; K E Anderson; E J Pantuck; C B Pantuck; R Chang; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

5.  Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man.

Authors:  K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 6.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

7.  Experience with perindopril in normal volunteers.

Authors:  B Waeber; J Nussberger; L Perret; J P Santoni; H R Brunner
Journal:  Clin Exp Hypertens A       Date:  1989

8.  Trial of atenolol and chlorthalidone for hypertension in black South Africans.

Authors:  Y K Seedat
Journal:  Br Med J       Date:  1980-11-08

9.  Blood distribution of tenoxicam in humans: a particular HSA drug interaction.

Authors:  F Bree; P Nguyen; S Urien; P Riant; E Albengres; H Fenner; J P Tillement
Journal:  Fundam Clin Pharmacol       Date:  1989       Impact factor: 2.748

10.  Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer.

Authors:  C Richer; C Thuillez; J F Giudicelli
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

View more
  4 in total

1.  Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese.

Authors:  Guo Yu; Hong-Hao Zhou; Qing-Shan Zheng; Guo-Fu Li
Journal:  Eur J Clin Pharmacol       Date:  2018-12-19       Impact factor: 2.953

Review 2.  Perindopril: an updated review of its use in hypertension.

Authors:  M Hurst; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability.

Authors:  Katarina Hatalova; Daniel Pella; Rastislav Sidlo; Robert Hatala
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

4.  The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.

Authors:  J J Brugts; M Bertrand; W Remme; R Ferrari; K Fox; S MacMahon; J Chalmers; M L Simoons; E Boersma
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.